Stentys has raised US$18 million
Stentys has raised US$18 million through private equity investment.
Stentys develops a new-generation stent designed for treatment of acute myocardial infarction and coronary artery bifurcations. Based in Princeton, New Jersey, and Paris, France, the company intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure.
Oaklins’ team in France advised Stentys on its two financing rounds, raising a total of US$18 million. The team continues to advise Stentys on corporate strategic matters.
Talk to the deal team
Related deals
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Learn moreWhite Lab has acquired Testing
White Lab Srl. has acquired Testing Srl.
Learn morePrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Learn more